摘要 目的：探讨免疫抑制疗法(IST)治疗儿童再生障碍性贫血(AA)的疗效、安全性及影响疗效的主要因素。方法：对2007年1月至2010年12月接受IST治疗的55例重型再生障碍性贫血（SAA）及51例慢性再生障碍性贫血（CAA）患儿的临床资料进行回顾性分析。结果：① 在CAA患儿中，抗胸腺球蛋白（ATG）联合环孢素A（CsA）治疗组总有效率明显高于CsA单独治疗组(80％ vs 44％，P40%、治疗前无重症感染以及有G-CSF早期治疗反应的患儿治疗效果较好，而治疗效果与AA分型、年龄等指标无关。结论：ATG+CsA联合治疗是治疗儿童AA的一种安全有效的方法；病程长短、有无严重感染、骨髓造血面积及G-CSF早期治疗反应是影响疗效的主要因素。
Abstract：OBJECTIVE: To study the effectiveness and safety of immunosuppressive therapy (IST) in the treatment of childhood aplastic anemia (AA) and to study the main factors influencing the effectiveness. METHODS: The clinical data of 55 children with severe aplastic anemia (SAA) and 51 children with chronic aplastic anemia (CAA) were retrospectively analyzed. All patients received IST from January 2007 to December 2010. RESULTS: In children with CAA, the effective rate of antithymocyte globulin (ATG) plus cyclosporine A(CsA) combination therapy was significantly higher than that of CsA alone (80% vs 44%; P<0.05); in children with SAA, the effective rate of ATG plus CsA combination therapy was also significantly higher than that of CsA alone (75% vs 40%; P<0.05). No patients developed clonal disease such as myelodysplastic syndrome, paroxysmal nocturn hemoglobinuria or acute myelocytic leukemia. In patients treated with the ATG plus CsA combination therapy, the response rate was relatively high for children whose disease course was less than six months, bone marrow hematopoietic area was more than 40%, had no severe infections, and experienced granulocyte colony stimulating factor (G-CSF) reaction during the early treatment; however, it was not related to AA subtypes and age. CONCLUSIONS: ATG plus CsA combination therapy is effective and safe in the treatment of childhood AA. The disease course, bone marrow hematopoietic area, severe infections and G-CSF reaction to early treatment are the main factors influencing the therapeutic effects.
［4］Frickhofen N, Heimpel H, Kahwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyelosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia［J］. Blood, 2003, 101(4): 1236-1242.
［5］Yamazaki H, Sugimori C, Chuhjo T, Nakao S. Cyclosporine therapy for acquired aplastic anemia: predictive factors for the response and long term prognosis［J］. Int J Hematol, 2007, 85(3): 186-190.
［7］Scheinberg P, Wu CO, Nunez O, Boss C, Sloand EM, Young NS. Treatment of severe aplastic anemia with a combination of horse antithymcyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study［J］. Haematologica, 2009, 94(3): 348-354.
［9］Scheinberg P, Wu CO, Nunez O, Young NS. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine［J］. J Pediatr, 2008, 153(6): 814-819.
［10］Passweg JR, Tichelli A. Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling［J］. Haematologica, 2009, 94(3): 310-312.
［11］Howard SC, Naidu PE, Hu XJ, Jeng MR, Rodriguez-Galindo C, Rieman MD, et al. Natural history of moderateaplastic anemia in children［J］. Pediatr Blood Cancer, 2004, 43 (5): 545-551.
［12］Marsh J, Schrezenmeier H, Matin P, Ilhan O, Ljungman P, McCann S, et al. Prospective randomized multicenter study comparing cyclosporine alone versus the combination of antithymocyte globulin and cyclosporine for treatment of patient with nosevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anemia Working Party［J］. Blood, 1999, 93(7): 2191-2195.
［13］Perez-Albuerne ED, Eapen M, Klein J, Gross TJ, Lipton JM, Baker KS, et al. Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia［J］. Br J Haematol, 2008, 141(2): 216-223.
［14］Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia［J］. Blood, 2006, 108(8): 2509-2519.
［15］Dufour C, Ferretti E, Bagnasco F, Burlando O, Lanciotti M, Ramenghi U, et al. Changes in cytokine profile pre-and post-immunosuppression in acquired aplastic anemia［J］. Heamatologica, 2009, 94 (12): 1743-1747.
［16］Scheinberg P, Nunez O, Young NS. Retreatment with rabbit antithymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anemia［J］. Br J Haematol, 2006, 133 (6): 622-627.
［17］Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic aneamia in children［J］. Br J Heamotol, 2007, 136(4): 549-564.
［18］Tichelli A, Schrezenmeier H, Socié G,Marsh J, Bacigalupo A, Dührsen U, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation［J］. Blood, 2011, 117(17): 4434-4441.
［19］Socie G, Mary JY, Sehrezenmerir H, Marsh J, Bacigalupo A, Locasciulli A, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT)［J］. Blood, 2007, 109(7): 2794-2796.
［20］Bacigalupo A, Brand R, Oneto R, Bruno B, Socié G, Passweg J, et a1. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunos uppressive therapy--The European Group for Blood and Marrow Transplantation experience［J］. Semin Hematol, 2000, 37(1): 69-80.
